Pacer Advisors’s Passage Bio PASG Stock Holding History

Pacer Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-106	Closed	-$37K	–	1508
2021 Q1	$37K	Buy	+106	New	+$45.3K	﹤0.01%	1470

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Pacer Advisors's PASG Position: Q2 2021 in Review

Pacer Advisors sold out of Passage Bio (PASG) in Q2 2021, closing a stake of 106 shares — an estimated $37K sold.

Pacer Advisors first reported a position in PASG in Q1 2021 and held it in 1 quarter. The position peaked at $37K in Q1 2021. 102 funds tracked by Wall St. Rank hold PASG as of Q2 2021.

Pacer Advisors reported no remaining Passage Bio position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 106 Passage Bio shares in Q2 2021, an estimated $37K.
Pacer Advisors first reported a position in Passage Bio in Q1 2021 and held it in 1 quarter.
Pacer Advisors's Passage Bio position peaked at $37K in Q1 2021.
102 funds tracked by Wall St. Rank held Passage Bio as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.